The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its future within the broader sector now presents questions about potential returns . Alternative versions are undercutting patent protection , causing anxieties that supporting companies significantly dependent to Viagra's previous position could